Does pneumococcal vaccine reduce influenza morbidity in humans?

被引:9
作者
Blay, A.
Bessler, H.
Lahad, A.
Waitman, D. A.
Djaldetti, M.
机构
[1] Rabin Med Ctr, Lab Immunol & Hematol Res, Petah Tiqwa, Israel
[2] Teva Pharmaceut Ind, Netanya, Israel
[3] Tel Aviv Univ, Sackler Sch Med, Ramat Aviv, Israel
[4] Hadassah, Dept Family Med, Jerusalem, Israel
[5] Hebrew Univ Jerusalem, Sch Med, IL-91010 Jerusalem, Israel
[6] Leumit Hlth Fund, Tel Aviv, Israel
关键词
pneumococcal vaccine; anti-influenza vaccine; influenza;
D O I
10.1016/j.vaccine.2006.09.056
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
A retrospective study was conducted to verify the possibility that people immunized with pneumococcal vaccine (PV) show lower morbidity not only for pneumonia but also for influenza. A total of 450 individuals were enrolled between 1999 and 2003 and allocated to one of the following groups: (A) not vaccinated; (B) immunized with PV during 1999; (C) immunized with anti-influenza vaccine (Flu-V) each year; and (D) immunized with PV once in 1999 and Flu-V every consecutive year. People from group B showed significantly lower percentage of influenza-related diseases during the year 2000 in comparison with those from group A (p < 0.01), whereas in the course of 2001 the morbidity of patients from group B was lower compared with the other groups (p < 0.01). The results point to a way to decrease the morbidity of influenza-related diseases by immunization with PV only, at least for 2-3 years, avoiding Flu-V administration and permitting considerable saving for health care providers. Therefore, it is concluded that PV can reduce the morbidity of influenza at a greater rate than the Flu-V. (c) 2006 Elsevier Ltd. All rights reserved.
引用
收藏
页码:1071 / 1075
页数:5
相关论文
共 30 条
[1]   Reducing medical service utilization by encouraging vaccines - Randomized controlled trial [J].
Berg, GD ;
Thomas, E ;
Silverstein, S ;
Neel, CL ;
Mireles, M .
AMERICAN JOURNAL OF PREVENTIVE MEDICINE, 2004, 27 (04) :284-288
[2]  
Bertz H, 2001, Fortschr Med Orig, V119 Suppl 2, P71
[3]   Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia [J].
Black, SB ;
Shinefield, HR ;
Ling, S ;
Hansen, J ;
Fireman, B ;
Spring, D ;
Noyes, J ;
Lewis, E ;
Ray, P ;
Lee, J ;
Hackell, J .
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2002, 21 (09) :810-815
[4]   Postlicensure evaluation of the effectiveness of seven valent pneumococcal conjugate vaccine [J].
Black, SB ;
Shinefield, HR ;
Hansen, J ;
Elvin, L ;
Laufer, D ;
Malinoski, F .
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2001, 20 (12) :1105-1107
[5]  
*CDCP, 1995, MMWR-MORBID MORTAL W, V274, P532
[6]   Effects of a large-scale intervention with influenza and 23-valent pneumococcal vaccines in adults aged 65 years or older:: a prospective study [J].
Christenson, B ;
Lundbergh, P ;
Hedlund, J ;
Örtqvist, Å .
LANCET, 2001, 357 (9261) :1008-1011
[7]   Additive preventive effect of influenza and pneumococcal vaccines in elderly persons [J].
Christenson, B ;
Hedlund, J ;
Lundbergh, P ;
Örtqvist, Å .
EUROPEAN RESPIRATORY JOURNAL, 2004, 23 (03) :363-368
[8]   Comparison between cohorts vaccinated and unvaccinated against influenza and pneumococcal infection [J].
Christenson, B ;
Lundbergh, P .
EPIDEMIOLOGY AND INFECTION, 2002, 129 (03) :515-524
[9]   IMMUNOGLOBULIN-G CLASS AND SUBCLASS ANTIBODIES TO PNEUMOCOCCAL CAPSULAR POLYSACCHARIDES [J].
CHUDWIN, DS ;
ARTRIP, SG ;
SCHIFFMAN, G .
CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY, 1987, 44 (01) :114-121
[10]  
D'Alessandro D, 2004, INDIAN J MED RES, V119, P108